At the last check on Friday, Collegium Pharmaceutical Inc.’s (NASDAQ:COLL) stock was up $2.98, moving up 13.53 percent to $25.00. The average number of shares traded per day over the past five days has been 339,468 shares. 2 times new highs have been achieved over the past 5 days, with a $2.52 gain in that time frame. In the last twenty days, the average volume was 250,767, while in the previous 50 days, it was 287,477.
Since last month, COLL stock rose 16.88%. Shares of the company fell to $20.83 on 07/06/23, the lowest level in the past month. A 52-week high of $30.22 was reached on 01/26/23 after having rallying from a 52-week low of $15.40. Since the beginning of this year, COLL’s stock price has risen by 7.76% or $1.77, and marked a new high 5 times. However, the stock has declined by -17.27% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
COLL stock investors should be aware that Collegium Pharmaceutical Inc. (COLL) stock had its last reported insider trading activity 39 days ago on Jun 26. Kuhlmann Shirley R., the EVP and General Counsel of the company, disposed of 17,984 shares for $21.72 on Jun 26. It resulted in a $390,633 divestment by the insider. Ciaffoni Joseph sold 31,272 shares at an average price of $21.60 on Jun 02. The insider now owns 275,000 shares following the transaction. On Jun 01, President and CEO Ciaffoni Joseph sold 31,272 shares at $22.09 apiece. The transaction was valued at $690,758.
Valuation Metrics
The stock’s beta is 0.84. Besides these, the trailing price-to-sales (P/S) ratio of 1.58, the price-to-book (PB) ratio of 4.77, and the price-to-cash flow ratio of 4.73 may also be considered.
Financial Health
In the three months ended June 29, Collegium Pharmaceutical Inc.’s quick ratio stood at 1.10, while its current ratio was 1.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 3.42, and the total debt-to-equity ratio was 4.44. On the profitability front, the trailing twelve-month gross margin is 46.30% percent. In the year ended June 29, EBITDA margin amounted to 43.93%, whereas operating margins totaled 8.50%. Based on annual data, COLL earned $209.49 million in gross profit and brought in $463.93 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.10%. Return on equity (ROE) for the past 12 months was -15.30%.
In Collegium Pharmaceutical Inc.’s quarter-end financial report for June 29, it reported total debt of $353.77 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. COLL’s revenue rose 17.79% to $87.34 million during the quarter, while net income inched up to $144.77 million. While analysts expected Collegium Pharmaceutical Inc. to report $0.29 quarterly earnings, the actual figure was $0.34 per share, beating the consensus estimate by 17.20%. During the quarter, the company generated $62.91 million in EBITDA. The liabilities of Collegium Pharmaceutical Inc. were 1.03 billion at the end of its most recent quarter ended June 29, and its total debt was $762.35 million. The value of shareholders’ equity is $34.59 million.
Technical Picture
This quick technical analysis looks at Collegium Pharmaceutical Inc.’s (COLL) price momentum. With a historical volatility rate of 72.19%, the RSI 9-day stood at 76.49% on 03 August.
With respect to its five-day moving average, the current Collegium Pharmaceutical Inc. price is up by +11.22% percent or $2.52. At present, COLL shares trade +14.86% above its 20-day simple moving average and +4.26% percent above its 100-day simple moving average. However, the stock is currently trading approximately +7.40% above its SMA50 and +36.82% above its SMA200.
Stochastic coefficient K was 62.38% and Stochastic coefficient D was 65.23%, while ATR was 1.01. Given the Stochastic reading of 90.60% for the 14-day period, the RSI (14) reading has been calculated as 70.70%. As of today, the MACD Oscillator reading stands at 0.55, while the 14-day reading stands at 0.66.
Analyst Ratings
Collegium Pharmaceutical Inc. (COLL) has been rated Buy by analysts. According to 0 brokerage firms, COLL is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Collegium Pharmaceutical Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $34.00, the current consensus forecast for the stock is $30.00 – $37.00. Based on these forecasts, analysts predict Collegium Pharmaceutical Inc. (COLL) will achieve an average price target of $33.75.
